

Specialty Products Pipeline

Phase 2	Phase 3	Registration	Recent Approvals	
Fremanezumab (anti CGRP) <i>Post-Traumatic Headache</i>	Fremanezumab (anti CGRP) <i>Cluster Headache</i>	Fremanezumab (anti CGRP) <i>Migraine (U.S. & E.U.)</i>	Austedo® <i>Huntington Disease (U.S.)</i>	<div style="text-align: center;"> <p>13 programs in Phase 2 through Registration</p> </div> <ul style="list-style-type: none"> Migraine & Pain 5 Neurology & Neuropsychiatry 3 Respiratory 2 Biosimilars 2 Other TA 1
Fasinumab ¹ <i>Chronic Lower Back Pain</i>	Fasinumab ¹ <i>Osteoarthritis pain</i>	Azilect® ⁴ <i>Parkinson's disease (Japan)</i>	Austedo® <i>Tardive dyskinesia (U.S.)</i>	
Laquinimod <i>Huntington disease</i>	Austedo® (SD-809) ² <i>Tourette Syndrome (U.S.)</i>	ProAir e-RespiClick® <i>E-connectivity (U.S.)</i>	ArmonAir® RespiClick® <i>Asthma (U.S.)</i>	
	Reslizumab SC ³ <i>Asthma (Global)</i>	CT-P10 ⁵ (<i>rituximab biosimilar</i>)	AirDuo® RespiClick® <i>Asthma (U.S.)</i>	
		CT-P6 ⁵ (<i>trastuzumab biosimilar</i>)	QVAR® RediHaler™ (beclomethasone dipropionate HFA) <i>Asthma (U.S.)</i>	
		BENDEKA® ⁶ <i>CLL and NHL (Growth Markets)</i>	Reslizumab IV ³ <i>Asthma (selective Growth Markets)</i>	
			Trisenox® <i>Acute Promyelocytic Leukemia (U.S.)</i>	

Note: Pipeline is current as of January 2018

¹In partnership with Regeneron

²In partnership with Nuvelution Pharma

³Approved in the U.S under the trade name CINQAIR®

⁴Submitted by Takeda

⁵In partnership with Celltrion

⁶In partnership with Eagle Pharmaceuticals